Abivax reported a net loss of EUR 336.1M for 2025, compared to a loss of EUR 176.2M the previous year, while its operating loss also widened from EUR 173M to EUR 246.1M.
This widening deficit primarily reflects an increase in operating expenses, with general and administrative costs rising by EUR 34.7M to EUR 67.7M, and R&D spending increasing by EUR 31.2M to EUR 177.8M.
The biotech firm held cash, cash equivalents, and short-term investments of EUR 530.4M at the end of 2025, providing a projected cash runway through the fourth quarter of 2027 based on current operating assumptions.
"With a solid cash position, we are well-positioned to execute our strategic priorities and prepare for the future," stated CEO Marc de Garidel, also highlighting the company's recent progress.
Abivax reported that the meeting of the independent Data Safety Monitoring Board (DSMB) for the Phase 3 ABTECT study, held on March 18, identified no new safety signals.
This positive update supports the continued advancement of the program, with the company remaining on track to release results from its ABTECT-UC maintenance trials at the end of the second quarter of 2026.
Finally, Abivax announced the appointment of Michael Nesrallah as Chief Commercial Officer, bringing extensive expertise in IBD to support the company's next phase of growth.
Abivax is a clinical-stage biotechnology company focused on the development of therapeutics that exploit the body's natural regulatory mechanisms to stabilize the immune response in patients suffering from chronic inflammatory diseases.
Based in France and the United States, Abivax's lead drug candidate, obefazimod (ABX464), is in Phase 3 clinical trials for the treatment of moderate to severe active ulcerative colitis.
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
-
Global
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
-
Quality
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
-
ESG MSCI
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
